PARIS / LONDON (IT BOLTWISE) – Sanofi recorded a remarkable jump in sales in the third quarter, largely driven by the successful drug Dupixent. With sales of over 4 billion euros for this drug alone, the group exceeded analysts’ expectations. Despite negative exchange rate effects, particularly from the USA, Sanofi was able to achieve an operating profit of 4.4 billion euros.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
Sanofi reported a significant increase in sales in the third quarter of 2023, mainly driven by the drug Dupixent. Dupixent, which is used in the treatment of asthma and neurodermatitis, achieved sales of over 4 billion euros in a quarter for the first time, which corresponds to growth of over 25 percent. This impressive performance exceeded analysts’ expectations and positively influenced market sentiment.
Although Sanofi’s total sales only increased by 2.3 percent to 12.4 billion euros, its operating profit of 4.4 billion euros was better than expected. This shows that Sanofi was able to increase its profitability despite the challenges posed by negative foreign exchange effects, particularly from the US. Adjusted profit rose 4 percent to 3.5 billion euros, underlining the company’s solid financial base.
Dupixent’s success is evidence of Sanofi’s strategic focus on innovative therapies. The drug has established itself as an important growth driver and contributes significantly to the company’s increase in sales. Sanofi has confirmed its annual targets, increasing confidence in the company’s future development.
In a competitive market environment, it is crucial for Sanofi to continue investing in research and development to consolidate its position and explore new growth opportunities. Dupixent’s positive development could serve as a model for future product innovations that have the potential to further transform the market.
*Order an Amazon credit card with no annual fee with a credit limit of 2,000 euros! a‿z
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ «KI Gadgets»
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Sanofi records record sales thanks to Dupixent”.
The post Sanofi records record sales thanks to Dupixent appeared first on Veritas News.
